CVS Health Lifts 2026 EPS Forecast, Q1 Profit Beats Estimates on Strong Cost Controls
CVS sits 42% above its 52-week low of $58.35.
Summary
CVS Health raised its 2026 adjusted EPS forecast to a range of $7.30-$7.50, up from $7.00-$7.20, and reported a first-quarter adjusted profit of $2.57 per share, significantly exceeding analyst estimates of $2.20. Total revenue also surpassed expectations at $100.4 billion. This positive guidance and strong Q1 performance, particularly the improved medical loss ratio of 84.6% (below estimates of 87.58%), indicate effective cost management and improved profitability in its health insurance business. This follows recent efforts by Aetna in standardizing prior authorizations and Caremark's formulary changes, suggesting these initiatives are yielding results. This is a material positive development that could significantly impact investor sentiment and stock valuation, especially given the company's previous goodwill impairment in its 2025 annual report. While the health services and benefits segments performed well, the pharmacy business saw an 8.8% decline in operating income, which investors will monitor alongside the company's ability to sustain cost control improvements.
At the time of this announcement, CVS was trading at $83.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $103.4B. The 52-week trading range was $58.35 to $85.15. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.